OSTX Seeks Shareholder Nod for Major Equity Issuance, Tripling Authorized Shares

TL;DR

**OSTX is gearing up for massive dilution and a potential takeover defense, signaling big strategic shifts ahead.**

AI Summary

OS Therapies Inc. (OSTX) is holding its 2025 Annual Meeting on October 14, 2025, to address several critical proposals impacting its corporate structure and financial flexibility. Key proposals include the election of six directors, and the approval of a significant issuance of common stock to Ayala Pharmaceuticals, Inc., potentially exceeding 20% of OSTX's outstanding common stock as of April 9, 2025, in connection with an asset purchase. The company also seeks to increase its authorized common stock from 50 million to 150 million shares and expand its 2023 Incentive Compensation Plan by 6 million shares, from 4 million to 10 million. Additionally, stockholders will vote on adopting a shareholder rights agreement and ratifying MaloneBailey, LLP as the independent auditor for fiscal year 2025. These measures are crucial for OSTX's strategic growth and operational funding, particularly the equity issuance and increased share authorization which could facilitate future capital raises or acquisitions.

Why It Matters

This DEF 14A filing reveals OS Therapies Inc.'s aggressive moves to bolster its financial and strategic position, which could significantly impact investors through potential dilution. The proposed issuance of over 20% of common stock to Ayala Pharmaceuticals, Inc. for an asset purchase, coupled with a request to increase authorized shares from 50 million to 150 million, signals a clear intent for future capital raises or strategic transactions. For employees, the expansion of the 2023 Incentive Compensation Plan from 4 million to 10 million shares could enhance retention and motivation. Customers and the broader market will watch how these financial maneuvers support OSTX's competitive standing in the biotech sector, especially concerning the HER2 Asset Purchase, as increased capital could accelerate product development and market penetration.

Risk Assessment

Risk Level: high — The risk level is high due to several proposals indicating potential significant dilution and a defensive posture. The Issuance Proposal seeks approval for issuing shares to Ayala Pharmaceuticals, Inc. 'equal to or exceeding 20%' of common stock outstanding as of April 9, 2025, which is substantial dilution. Furthermore, the Charter Amendment Proposal to increase authorized common stock from 50 million to 150 million shares, a 200% increase, creates capacity for further significant dilution without additional shareholder approval. The Rights Agreement Resolution Proposal, often referred to as a 'poison pill,' indicates the board is preparing for potential hostile takeover attempts, which can entrench management and deter premium offers.

Analyst Insight

Investors should carefully evaluate the potential for significant dilution from the proposed share issuance to Ayala Pharmaceuticals and the substantial increase in authorized shares. Consider voting against the Charter Amendment Proposal and the Issuance Proposal if you are concerned about dilution, and scrutinize the details of the shareholder rights agreement for its impact on shareholder value and corporate governance.

Key Numbers

• 6 — Number of directors to be elected (Serving until the 2026 annual meeting)
• 20% — Minimum percentage of common stock to be issued to Ayala Pharmaceuticals, Inc. (Exceeding 20% of common stock outstanding as of April 9, 2025)
• 50 million — Current authorized shares of common stock (Proposed to increase to 150 million)
• 150 million — Proposed authorized shares of common stock (A 200% increase from 50 million)
• 4 million — Current shares available under 2023 Incentive Compensation Plan (Proposed to increase to 10 million)
• 10 million — Proposed shares available under 2023 Incentive Compensation Plan (An increase of 6 million shares)
• 31,645,015 — Shares of common stock outstanding (As of the Record Date, August 20, 2025)
• 567,500 — Shares of Series A preferred stock outstanding (As of the Record Date, August 20, 2025)
• 600,529 — Common stock equivalent for Series A preferred stock voting (As of the Record Date, August 20, 2025)

Key Players & Entities

• OS Therapies Incorporated (company) — Registrant and issuer of common stock
• Ayala Pharmaceuticals, Inc. (company) — Recipient of common stock in asset purchase transaction
• Paul A. Romness, MPH (person) — President and Chief Executive Officer, and Chairman of OS Therapies Inc.
• MaloneBailey, LLP (company) — Independent registered public accounting firm for fiscal year ending December 31, 2025
• NYSE American LLC (regulator) — Exchange requiring approval for share issuance
• VStock Transfer, LLC (company) — Stock transfer agent for OS Therapies Inc.
• SEC (regulator) — Securities and Exchange Commission

FAQ

Industry Context

OS Therapies Inc. operates within the biotechnology and pharmaceutical sector, a highly competitive and research-intensive industry. Companies in this space often rely on strategic partnerships, asset acquisitions, and significant capital raises to fund drug development and commercialization efforts. The industry is characterized by long development cycles, high R&D costs, and stringent regulatory oversight from bodies like the FDA.

Regulatory Implications

The proposed issuance of over 20% of common stock and the increase in authorized shares may trigger specific disclosure requirements or review by stock exchange listing committees (e.g., NYSE American LLC Company Guide Section 713(a)). Companies must ensure compliance with securities laws regarding equity issuances and shareholder approvals.

What Investors Should Do

1. Review the proposals regarding the issuance of common stock to Ayala Pharmaceuticals and the increase in authorized shares to understand the potential dilution and strategic implications for future capital structure.
2. Evaluate the election of directors to ensure alignment with the company's strategic direction and governance standards.
3. Consider the adoption of the shareholder rights agreement and its potential impact on future corporate control and shareholder rights.
4. Assess the proposed expansion of the 2023 Incentive Compensation Plan and its potential dilutive effect on existing shareholders.
5. Confirm the ratification of Malone Bailey, LLP as the independent auditor, ensuring confidence in the company's financial reporting.

Key Dates

• 2025-10-14: 2025 Annual Meeting of Stockholders — Key proposals impacting corporate structure, financial flexibility, and director elections will be voted on.
• 2025-09-04: Mailing of Notice of Internet Availability of Proxy Materials — Informs stockholders of the availability of proxy materials for the annual meeting.
• 2025-08-20: Record Date — Determines which stockholders are eligible to vote at the Annual Meeting.
• 2025-04-09: Date for determining outstanding common stock for Ayala Pharmaceuticals issuance — Establishes the baseline for calculating the significant equity issuance to Ayala Pharmaceuticals.
• 2025-03-31: Filing of Annual Report on Form 10-K for fiscal year ended December 31, 2024 — Provides audited financial statements and comprehensive company information for the prior fiscal year.

Glossary

DEF 14A

A proxy statement filed with the SEC by publicly traded companies to solicit shareholder votes for an upcoming meeting. (This document contains the proposals and information necessary for shareholders to make informed voting decisions at the OS Therapies Inc. 2025 Annual Meeting.)

Common Stock

A class of stock that represents ownership in a corporation and entitles the owner to a proportionate claim on the corporation's assets and earnings. (The issuance of common stock to Ayala Pharmaceuticals and the increase in authorized common stock are central proposals in this filing.)

Authorized Shares

The maximum number of shares of stock that a corporation is legally permitted to issue, as specified in its charter. (OS Therapies Inc. is seeking to significantly increase its authorized shares to facilitate future transactions.)

Incentive Compensation Plan

A plan designed to reward employees and directors for achieving specific performance goals, often through stock options or awards. (The company is proposing to increase the number of shares available under its 2023 Incentive Compensation Plan.)

Shareholder Rights Agreement

A contract that gives shareholders certain rights, often triggered by a hostile takeover attempt, to protect their investment. (The adoption of a shareholder rights agreement is one of the proposals to be voted on at the meeting.)

Independent Auditor

An external accounting firm hired to audit a company's financial statements to ensure accuracy and compliance with accounting standards. (Shareholders will vote on ratifying Malone Bailey, LLP as the independent auditor for fiscal year 2025.)

Asset Purchase

A transaction where a buyer purchases specific assets of a seller's business, rather than the entire business entity. (The issuance of stock to Ayala Pharmaceuticals is in connection with an asset purchase, indicating a strategic transaction.)

Record Date

A specific date set by a company to determine which shareholders are eligible to receive dividends, vote on corporate matters, or receive other distributions. (The Record Date of August 20, 2025, determines eligibility to vote at the October 14, 2025, Annual Meeting.)

Year-Over-Year Comparison

This DEF 14A filing for the 2025 Annual Meeting focuses on significant corporate actions and financial restructuring, including a substantial equity issuance and a tripling of authorized shares. Unlike a typical annual report, it details proposals requiring shareholder approval for strategic growth and funding. Specific comparative financial metrics from the prior year's filing (e.g., revenue growth, margin changes) are not directly presented within this proxy statement, which primarily addresses upcoming votes and governance matters.

Filing Documents

• ea0251913-03.htm (DEF 14A) — 1808KB
• tos_logo.jpg (GRAPHIC) — 83KB
• tos_logo1.jpg (GRAPHIC) — 83KB
• tproxy_001.jpg (GRAPHIC) — 1171KB
• tproxy_002.jpg (GRAPHIC) — 1274KB
• 0001213900-25-080407.txt ( ) — 8551KB
• ostx-20250825.xsd (EX-101.SCH) — 9KB
• ostx-20250825_lab.xml (EX-101.LAB) — 33KB
• ea0251913-03_htm.xml (XML) — 3KB

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 30

Executive Compensation

Executive Compensation 32 Non-Employee Director Compensation 36 Certain Relationships and Related Party Transactions 37 Report of the Audit Committee 39 Delinquent Section 16(a) Reports 40 Shareholder Proposals for Next Annual Meeting 41 Householding 42 Where to Get Additional Information 43 Other Matters 44 i Table of Contents OS THERAPIES INCORPORATED PROXY STATEMENT FOR ANNUAL MEETING OF STOCKHOLDERS To Be Held at 10:00 a.m., Eastern time, on October 14, 2025 This Proxy Statement and the enclosed form of proxy are furnished in connection with the solicitation of proxies by our board of directors for use at our 2025 Annual Meeting of Stockholders, and any postponements, adjournments or continuations thereof (the "Annual Meeting"). The Annual Meeting will be held on October 14, 2025, at 10:00 a.m., Eastern time, in a virtual meeting format. References in this Proxy Statement to "we," "us," "our" or "the Company" refer to OS Therapies Incorporated. Our board of directors is sending a Notice of Internet Availability of Proxy Materials (the "Notice of Internet Availability") relating to the Annual Meeting to the Company's stockholders beginning on or about September 4, 2025. The Notice of Internet Availability instructs you on how to access and review this Proxy Statement and our Annual Report on Form 10 -K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission (the "SEC") on March 31, 2025 (our "Annual Report"). The information included in this Proxy Statement relates to the proposals to be voted on at the Annual Meeting, the voting process, the compensation of our named executive officers and our directors, and certain other required information. Important Notice of Internet Availability of Proxy Materials for the 2025 Annual Meeting of Stockholders to be held on October 14, 2025 The Notice of Internet Availability, this Proxy Statement and our Annual Report are available through the Intern

View Full Filing

View this DEF 14A filing on SEC EDGAR